Chapel Hill, NC – Susan G. Komen for the Cure® has awarded a grant of almost $900,000 to Lisa A. Carey, MD, and Gary Johnson, PhD, to research clinical applications for the first broad-based test for protein kinase activation and response to inhibitory drugs in HER2-positive breast cancer.
The finding presents a possible explanation for why so many cancers possess not just genomic instability, but also more or less than the usual 46 DNA-containing chromosomes.
Chapel Hill, NC – Multiple myeloma is a form of cancer where the plasma cells in the bone marrow grow out of control, causing damage to bones as well as predisposing patients to anemia, infection and kidney failure. A medical procedure called autologous hematopoietic stem cell transplantation, commonly known as a stem cell transplant, is frequently an important treatment option for many patients.
Chapel Hill - Cancer therapies targeting specific molecular subtypes of the disease allow physicians to tailor treatment to a patient’s individual molecular profile. But scientists are finding that in many types of cancer the molecular subtypes are more varied than previously thought and contain further genetic alterations that can affect a patient’s response to therapy.
Chapel Hill, NC –A medical procedure called allogeneic hematopoietic cell transplantation, commonly known as a bone marrow or stem cell transplant, is the only known curative option for many patients with life-threatening blood-borne cancers such as leukemia and lymphoma.
Jason Lieb likes to mix it up. A triathlete, he enjoys running, swimming and cycling. In his lab, he works in several model systems: yeast, round worms (C. elegans), fruit flies (Drosophila melanogaster) and human cell lines.
Idoia Garcia, PhD, a postdoctoral fellow in the lab of Timothy Gershon, MD, PhD, has been awarded a Department of Defense Visionary Postdoctoral Fellowship Award. The peer-reviewed award is intended to support exceptionally talented recent medical or other doctoral graduates in their pursuit of cutting-edge, innovative, high-risk/high-impact cancer research during their postdoctoral fellowship.
Channing Der, PhD, Sarah Graham Kenan Professor of Pharmacology, received a two-year $200,000 American Association for Cancer Research Innovative grant from the Pancreatic Cancer Action Network. His grant will fund research on the mechanism of ERK inhibition resistance and ERK-dependent pancreatic cancer.
American and Spanish researchers report potential ways for doctors to improve the treatment of hormone receptor-positive breast cancer even if they lack access to costly multi-gene tests.
Which treatment for prostate cancer is most effective? Will a specific combination of cancer drugs increase patient survival for colon cancer? As the pace of scientific discovery continues to accelerate, patients and their providers face more choices and decisions about how to address their health care needs, and information that can help inform their decisions is often hard to find.